Rivaroxaban Tablet
Product Images NDC 42571-345

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 42571-345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Micro Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rivaroxaban-fig11.jpg (Rivaroxaban Fig11)

A cumulative incidence rate chart comparing Rivaroxaban and placebo over days from randomization up to approximately 1095 days. The solid line represents Rivaroxaban, and the dashed line represents placebo, with cumulative incidence rates on the y-axis and days on the x-axis. The chart includes a table below showing the number of subjects at risk at various time points for both groups.*

FDA Label Image

Rivaroxaban-fig12.jpg (Rivaroxaban Fig12)

A forest plot chart comparing the primary efficacy outcome of Rivaroxaban versus placebo, showing hazard ratios (HR) and 95% confidence intervals (CI) across various subgroups such as age, sex, weight, eGFR levels, baseline diabetes, coronary artery disease, randomization strata, clopidogrel use at randomization, history of revascularization, and critical limb ischemia categories. The plot visually indicates which treatment each subgroup favors.*

FDA Label Image

Rivaroxaban-fig2.jpg (Rivaroxaban Fig2)

A forest plot chart displaying fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of rivaroxaban relative to reference across various population groups, including end-stage renal disease, renal impairment severity levels, age ranges, body weight categories, and hepatic impairment statuses.*

FDA Label Image

Rivaroxaban-fig3.jpg (Rivaroxaban Fig3)

A chart depicting the pharmacokinetic impact of various interacting drugs on Rivaroxaban. It shows fold change and 90% confidence intervals for Cmax and AUC parameters with grouped drugs such as Combined P-gp and Strong CYP3A Inhibitors, Moderate CYP3A Inhibitors, Strong CYP3A Inducers, and other drugs relative to Rivaroxaban alone.*

FDA Label Image

Rivaroxaban-fig9.jpg (Rivaroxaban Fig9)

A forest plot comparing efficacy outcomes between Rivaroxaban and placebo across various subgroups, including age, sex, region, weight, eGFR, myocardial infarction history, stroke history, history of prior heart failure, baseline diabetes, and peripheral artery disease (PAD). The plot displays hazard ratios (HR) with 95% confidence intervals to illustrate relative effects on the composite of stroke, myocardial infarction, or cardiovascular death.*

FDA Label Image

Rivaroxaban-labla.jpg (Rivaroxaban Labla)

Rivaroxaban 2.5 mg tablets label showing the product name, strength, and dosage form. The label specifies storage instructions, dispensing guidelines, and manufacturer details, including Micro Labs Limited in India and Micro Labs USA, Inc. in New Jersey. The package contains 30 tablets for oral use, with the NDC code 42571-345-30.*

FDA Label Image

Rivaroxaban-str-1.jpg (Rivaroxaban Str 1)

Chemical structure diagram of rivaroxaban, showing its molecular components with rings and functional groups, consistent with the active ingredient rivaroxaban.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.